Blam­ing Covid dis­rup­tion, sup­ply short­ages, mi­cro­cap biotech hits the brakes on cell ther­a­py tri­al

More than two years in­to the Covid-19 pan­dem­ic, we’re not done see­ing its dis­rup­tion of biotech.

That’s ac­cord­ing to Cal­adrius ex­ecs, who cit­ed the pan­dem­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER